+25.0%
ORCL vs MRNA
-25.6%
+50.7%
-65.8%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 5y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -2.9% | +1.3% | -4.2% | -3.0% |
| 7D | -13.0% | -13.8% | +0.8% | -12.3% |
| 30D | -15.7% | -17.7% | +2.0% | -14.9% |
| 3M | -22.8% | +14.3% | -37.1% | -23.7% |
| 6M | -38.6% | +336.0% | -374.6% | -47.0% |
| YTD | -42.5% | +575.9% | -618.4% | -53.2% |
| 1Y | -50.3% | +724.4% | -774.7% | -60.6% |
| 3Y | -0.7% | +160.8% | -161.5% | -15.3% |
| All | +25.0% | -25.6% | +50.7% | +9.1% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 5y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
5y analysis · Full analysis span regression · 6 months rolling